Management Team

Stephen T. Lundy

President, Chief Executive Officer

Stephen T. Lundy was appointed to the positions of Chief Executive Officer and President on March 24, 2010. Effective on the same date, he was appointed to the Company's Board of Directors. Mr. Lundy has more than 20 years of experience in drug and diagnostic product development and commercialization. He most recently was Chief Executive Officer of MicroPhage from 2008 to 2010. Mr. Lundy was Senior VP of sales and marketing for Vermillion from 2007 to 2008. Mr. Lundy joined Vermillion from GeneOhm (2003-2007), a division of Becton, Dickinson and Company Diagnostics, where he served as Vice President of Sales and Marketing. At GeneOhm, Mr. Lundy successfully led the commercial launch of several novel molecular diagnostic assays including the first molecular test for Methicillin resistant Staphylococcus aureus. From 2002 to 2003, Mr. Lundy served as Vice President of Marketing for Esoterix, Inc., which was acquired by Laboratory Corporation of America, and he led the commercial integration and re-branding of the numerous reference labs acquired by Esoterix. Prior to Esoterix, he served as Marketing Director for Molecular Diagnostics and Critical Care Testing at Bayer Diagnostics Corporation. Mr. Lundy graduated from the United States Air Force Academy with a Bachelor of Science and was an officer with the United States Air Force from 1983 to 1988.

Jeffrey G. McGonegal

Chief Financial Officer

Jeffrey McGonegal became Chief Financial Officer of the Company in June 2003, was appointed Corporate Secretary in January 2010, and served as interim President in December 2004 and January 2005. Mr. McGonegal previously served on a part time basis from 2003 to 2010 as Chief Financial Officer of PepperBall Technologies, Inc. He had previously served as Chief Financial Officer of Bactolac Pharmaceutical, Inc. and had been associated with its predecessors through October 2006. From 1974 to 1997, Mr. McGonegal was an accountant with BDO Seidman LLP where he last served as Managing Partner of the Denver, Colorado office. Mr. McGonegal was elected in 2005 to serve on the board of Imagenetix, Inc., a publicly held company in the nutritional supplements industry. He received a Bachelor of Arts degree in Accounting from Florida State University.

Erik Miller

Vice President of Marketing and Business Development

Erik Miller joined AspenBio Pharma as a consultant in October 2010 and became Vice President in January 2011. Mr. Miller has over twenty years of experience focused on health care marketing, management, sales, and business development. Most recently he served as Vice President, Business Development and Marketing for Radix Biosolutions which launched its first commercial products and defined services during his tenure. Previously, he worked in increasing levels of marketing and business responsibility with Luminex Corporation, Safety Syringes, Inc. and Biosite Diagnostics. Mr. Miller received a Bachelor of Science degree in Pharmacy from the University of Iowa and a Masters in Business Administration from the University of North Carolina at Chapel Hill.

Dr. Mary Nunnally

Vice President of Quality

Mary Nunnally joined AspenBio Pharma in September 2009 as Vice President of Quality. She has nearly 15 years of experience in the pharmaceutical, medical device, diagnostics, and medical research products industries primarily in the areas of Quality Assurance, Quality Control and Analytical Method Development/Validation. She has also provided leadership and technical expertise to multidisciplinary teams focused on New Product Development, acting as a liaison between R&D and Operations to ensure smooth product transitions between research and commercialization. More recently, as Director of Technical Operations at Ceragenix Pharmaceuticals she was responsible for all aspects of product scale-up, validation, quality, and ongoing contract manufacturing for a new prescription medical device developed for the management of eczema. Prior to entering industry, Dr. Nunnally did her postdoctoral research and was a Research Assistance Professor of Pharmacology and Physiology at the University of Texas Southwestern Medical Center at Dallas. Dr. Nunnally received her Bachelor of Arts in Genetics from the University of California, Berkeley and Ph.D. in Biochemistry from the Johns Hopkins University School of Medicine.

Gregory Pusey

Vice President

Gregory Pusey became a director of AspenBio Pharma, Inc. in February 2002. Throughout his involvement with AspenBio, he has assisted with consulting, financings, and strategic direction. Until his resignation in April 2011, Mr. Pusey had served as a director of PepperBall Technologies, Inc. and its predecessors since 2002. Since 1988, Mr. Pusey has been the President and a director of Cambridge Holdings, Ltd. which currently has limited activities. Mr. Pusey is a director and assistant secretary of Bactolac Pharmaceutical, Inc., a privately held company engaged in manufacturing and marketing of vitamins and nutritional supplements. Over the last 35 years, Mr. Pusey has helped a variety of companies with corporate development and financing activities. Mr. Pusey graduated from Boston College with a Bachelor of Science degree in Finance.

Dr. Michael Wandell

Regulatory and Clinical Affairs

Dr. Wandell is a clinical pharmacologist and pharmacokineticist with a record of successfully managing large scale clinical research programs and regulatory submissions delivering innovative biologic and medical products to world-wide markets. His knowledge of ICH GCPs, GLPs and Quality Systems Regulations has produced rapid approvals from FDA and international regulatory agencies. Dr. Wandell's experience includes Senior Vice President, Clinical, Regulatory, and Quality of Epigenomics GmbH, a fully integrated molecular diagnostics company, where he was the architect and Study Director of the PRESEPT Study, and Program Director of Clinical Research at Benaroya Research Institute, an internal site management organization responsible for conducting more than 200 clinical research studies annually on behalf of pharma, biologic, and medical device companies within the Virginia Mason Health System in the Seattle, Washington area. He has also been Study Director for numerous multicenter clinical investigations conducted world-wide on behalf of Syntex, Genetic Systems Corportion, Sanofi and Home Access Health Corporation. Dr. Wandell's clinical development and regulatory submissions have produced registration of licensed biologicals and medical devices in the US (BLAs, PMAs, 510ks), EU, Japan, Canada and Australia. In addition, Dr. Wandell has submitted and received approval for several licensed IVD biological and medical device products (HIV, HTLV, Hepatitis B & C) as well as conducted clinical studies for licensure or clearance for numerous in vitro diagnostic products in the United States and world-wide markets.